Loading
A phase 2 trial of Rovalpituzumab tesirine in Small-cell lung cancer, run by AbbVie, completed.
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer is a phase 2 interventional study registered as NCT02674568 by AbbVie, with 342 participants recorded, started 2016-01-25 and reaching its primary completion in 2018-10-19. Interventions recorded: Rovalpituzumab tesirine. Conditions recorded: Small Cell Lung Cancer.
Linked to the drug Rovalpituzumab tesirine because the registry names it among its interventions and Small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
342 enrolled.
95% CI 4.7 to 5.8; Figures from the ClinicalTrials.gov results section (first posted 2019-10-23), not from a publication · 95% CI 4.7 to 5.8
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Survivalprimary | Rovalpituzumab Tesirine: DLL3 High | 238 | 5.3 months | - | - | link |
| Rovalpituzumab Tesirine: DLL3 Positive | 287 | 5.3 months |
Shares Rovalpituzumab tesirine, AbbVie (incl. ImmunoGen, Capstan), Small-cell lung cancer and the tag pipeline.
Shares Rovalpituzumab tesirine, AbbVie (incl. ImmunoGen, Capstan), Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag pipeline.
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.